Myasthenia gravis is an immune disease mediated by antibodies,often manifested as skeletal muscle weakness and fatigue,treatment using traditional drugs usually can achieve good results,but there are still some patients whose symptoms have not been well improved,so the development of new drugs is very important.And zilucoplan injection ( trade name:Zilbrysq ) is a complement inhibitor,a new drug for the treatment of myasthenia gravis.The US FDA approved zilucoplan injection on October 17,2023.The pharmacological action,mechanism of action,pharmacokinetics,and usage and dosage of zilucoplan were briefly introduced in this paper,aiming to provide reference for its clinical use.
维普
万方数据